2022
PRESENCE OF BRCA MUTATIONS AND A PRE-CHEMOTHERAPY AMH LEVEL OF < 2ng/ML STRONGLY PREDICT RISK OF AMENORRHEA IN WOMEN WITH BREAST CANCER
Oktay K, Turan V, Bedoschi G, Goldfarb S, Bang H. PRESENCE OF BRCA MUTATIONS AND A PRE-CHEMOTHERAPY AMH LEVEL OF < 2ng/ML STRONGLY PREDICT RISK OF AMENORRHEA IN WOMEN WITH BREAST CANCER. Fertility And Sterility 2022, 118: e231. DOI: 10.1016/j.fertnstert.2022.08.652.Peer-Reviewed Original ResearchFertility Preservation in Breast Cancer Patients
Marin L, Turan V, Oktay K. Fertility Preservation in Breast Cancer Patients. 2022, 185-198. DOI: 10.1007/978-3-030-47767-7_14.Peer-Reviewed Original ResearchFertility preservation issuesBreast cancerGonadotropin-releasing hormone agonistNovel chemotherapy regimensSafety of pregnancyFertility preservation techniquesBreast cancer survivorsBreast cancer patientsBreast cancer survivalPremature ovarian insufficiencyBreast cancer treatmentChemotherapy regimensOvarian suppressionPremenopausal womenOvarian reserveHormone agonistCancer survivorsCommon malignancyFertility preservationOvarian functionCancer patientsCancer survivalBRCA mutationsSexual dysfunctionFertility risks
2018
Increased chemotherapy-induced ovarian reserve loss in women with BRCA mutations: a prospective longitudinal study with mechanistic confirmation
Oktay K, Bedoschi G, Goldfarb S, Titus S, Palomaki G, Dickler M. Increased chemotherapy-induced ovarian reserve loss in women with BRCA mutations: a prospective longitudinal study with mechanistic confirmation. Fertility And Sterility 2018, 110: e430. DOI: 10.1016/j.fertnstert.2018.08.035.Peer-Reviewed Original Research
2015
Safety of controlled ovarian stimulation with gonadotropins and letrozole in women with BRCA mutations
Kim J, Turan V, Oktay K. Safety of controlled ovarian stimulation with gonadotropins and letrozole in women with BRCA mutations. Fertility And Sterility 2015, 104: e265. DOI: 10.1016/j.fertnstert.2015.07.832.Peer-Reviewed Original ResearchChapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment
Turan V, Oktay K. Chapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment. 2015, 47-61. DOI: 10.1016/b978-0-12-801591-9.00004-7.Peer-Reviewed Original ResearchCancer treatmentComplications of chemotherapySystemic lupus erythematosusPremature ovarian insufficiencyQuality of lifeOvarian damageLupus erythematosusOvarian toxicityAutoimmune diseasesOvarian functionBRCA mutationsReproductive ageRelative riskChemotherapy agentsClinical dataOvarian insufficiencySurvival rateChemotherapeutic agentsOvarian cellsChemotherapyHuman dataTreatmentCurrent understandingErythematosusComplications
2009
Association of BRCA1 mutations with diminished ovarian reserve: A common genetic mechanism for breast/ovarian cancer, and infertility?
Oktay K, Kim J, Barad D, Gleicher N, Babayev S. Association of BRCA1 mutations with diminished ovarian reserve: A common genetic mechanism for breast/ovarian cancer, and infertility? Journal Of Clinical Oncology 2009, 27: 11039-11039. DOI: 10.1200/jco.2009.27.15_suppl.11039.Peer-Reviewed Original ResearchRelative riskOvarian reserveBRCA mutationsBreast cancerFertility preservationHereditary breast-ovarian cancer syndromeOocyte reserveBRCA1 mutationsBreast-ovarian cancer syndromeOvarian stimulation protocolsDiminished ovarian reservePreservation of fertilityPossible higher riskOvarian cancer syndromeNumber of oocytesBreast/ovarian cancerPoor response ratesInfertility historyPoor respondersBC patientsMean ageNon-invasive methodOvarian failureOvarian cancerBRCA2 mutations